William H. Maisel, MD, MPH Director, Medical Device Safety Institute Beth Israel Deaconess Medical Center Statement to the FDA Risk Communication Advisory.

Slides:

Advertisements

Similar presentations

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.

Advertisements

A Process of Quality Improvement: Informed Participation and Institutional Process SACHRP March 27, 2008 Nancy Neveloff Dubler Director Center for Ethics.

CPSC’s Public Data Base Tom Schroeder 10/11 *This presentation was prepared by CPSC staff. It has not been reviewed or approved by, and may not necessarily.

Automated External Defibrillation

Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.

Safety Alerts and Recalls on Heart Devices : ICDs & Pacemakers. Presevter: Emanuel CIS 763 PRESENTATION BC/CUNY.

FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.

Prevention of Sudden Cardiac Death Ali Shakir, MD Medical Director, Electrophysiology Services Henry Ford Macomb Hospital September 17th, 2011.

Testing a New Product Message for Medtronic’s Reveal Plus Insertable Loop Recorder Julie Gilbert May 19, 2003.

What Patients Need and Want to Know from their Physicians FDA Perspective Brian Lewis, MD, Medical Reviewer, FDA Division of Cardiovascular Devices Electrophysiologist,

External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.

Office of Safe and Drug-Free Schools Advisory Committee Meeting February 21, 2007.

Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.

FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.

Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

Consumer Awareness, Understanding, and Perceptions of Recalls of FDA- Regulated Products Amy Lando, MPP Center for Food Safety and Applied Nutrition U.S.

1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.

Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 

FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.

What is Food Recall A food recall is a voluntary action by a manufacturer or distributor to protect the public from products that may cause health problems.

Investing in Patient Care & Member Involvement Through Clinical Research.

Joint comment by The Nutrition Society of South Africa Association for Dietetics in South Africa Presented by Prof Johann Jerling Medicines and Related.

What is ACCPAC? ACCPAC is ACC’s political action committee ACCPAC opens the door and assures a seat at the table with key members of Congress 100% of personal.

RISK MANAGEMENT OVERVIEW 2014 Louise E. Swensen, JD, MS, CPHRM Associate Director.

Wireless Cardiac Device Monitoring Presented by: Ashley D. Solomon, RN Nursing 457: Nursing Informatics Fall 2009.

NC STATE UNIVERSITY 1 Michael S. Wogalter& Jennifer A. Cowley Cognitive Ergonomics Laboratory Department of Psychology North Carolina State University.

Bibliography Amoore, J., Ingram, P. (2002, August). Quality improvement report: Learning from adverse incidents involving medical devices. British Medical.

Smallpox Vaccine Program: Communications with the Public and Stakeholders Department of Health and Human Services Centers for Disease Control and Prevention.

1 Best Practices in Stakeholder Involvement Paul J. Seligman, M.D., M.P.H. Associate Director, Safety Policy & Communication Center for Drug Evaluation.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

The Quality Colloquium at Harvard University August 27, 2003 Patient Safety Organizational Readiness Assessment Tool Louis H. Diamond, MDBeverly A. Collins,

FDA Public Meeting on Electronic Records and Signatures June 11, 2004 Presentation of the Industry Coalition on 21CFR Part 11 Alan Goldhammer, PhD Chair.

Program to integrate Technology and Cardiac Arrest Resuscitation Background Cardiac arrest is characterized by sudden unexpected collapse caused by a loss.

Physicians and Health Information Exchange (HIE) The Value of HIE to a Physician’s Practice and Consumers.

Improving Population Health through Effective Public-Private Partnerships LaQuandra S. Nesbitt, MD, MPH Director, DC DOH October 27, 2015.

Heart Failure Coordinator Jocelyn McCullough, APPN, ACNS-BC, CHFN X76775

RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.

Investigational Devices and Humanitarian Use Devices June 2007.

1 Quality Initiatives in the Convenient Care Setting Sandra F. Ryan, MSN, CPNP Co-Chair, Convenient Care Association Clinical Advisory Board Chief Nurse.

Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.

What is Clarity for a FDA Patient Information Sheet? Susan Kleimann, Ph.D. Executive Director Center for Plain Language Washington, DC.

BDH Discovering Tomorrow’s Healthcare Solutions Today Clinical Research Services, Inc. Basil Halliday, M.Sc. President & CEO BDH Clinical Research Services.

FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,

1 Presentation of the Pharmaceutical Research and Manufacturers of America at FDA Part 15 Hearing on Communication of Drug Safety Information December.

INTERNATIONAL SCIENCE AND ENGINEERING FAIR Rules and Guidelines 2016.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Complaint and recall 1. Title 21--food and drugs Chapter I- food and drug administration department of health and human services Subchapter A- General.

The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration

FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.

Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.

0 Case Study 1 Advertising. ACADEMY OF OPHTHALMOLOGY Disclosure  The speaker has no financial interest in the subject matter of this.

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

U.S. FDA Center for Devices and Radiological Health Update

Deactivating the shocking component of an Implantable Cardioverter Defibrillator (ICD) (When no longer appropriate)

Innovation: A Priority for FDA

FDA-CDRH in the Next Decade A Vision for Change

NHLBI Perspective Yves Rosenberg, M.D, M.P.H.

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

CAP Test Ordering Program

FDA Resources and Meetings

EDUCATE: A NESTcc Demonstration Project Regulatory Perspective

Volume 6, Issue 10, Pages (October 2009)

Comparing Options for Management:PAtient-centered REsults for Uterine Fibroids Evan R. Myers, MD, MPH Department of Obstetrics & Gynecology and Duke Clinical.

Volume 11, Issue 2, Pages (February 2014)

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

FDA Sentinel Initiative

Tobey Clark, Director*, Burlington USA

Volume 7, Issue 11, Pages (November 2010)

Automated External Defibrillation

Presentation transcript:

William H. Maisel, MD, MPH Director, Medical Device Safety Institute Beth Israel Deaconess Medical Center Statement to the FDA Risk Communication Advisory Committee August 14, 2008 No Industry Relationships to Disclose

William H. Maisel, MD, MPH Overview of Comments HRS Background HRS Experience with Product Notifications Why Medical Devices Are Different Terminology For Medical Device Issues Communication Emerging Issues

William H. Maisel, MD, MPH Heart Rhythm Society International leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Represents ~ 5,000 specialists in cardiac pacing and electrophysiology. Arrhythmias are the leading cause of heart disease-related death, with sudden cardiac arrest claiming hundreds of thousands of American lives each year. Millions of additional patients have implanted cardiac rhythm management devices (Pacemakers and Implantable Defibrillators).

William H. Maisel, MD, MPH Heart Rhythm Society Tools of Our Trade Images from Google Image Search

William H. Maisel, MD, MPH Why Devices Are Different May Be Permanent Implant Not Easily Removed Sophisticated Technology Experience “Normal” Wear and Tear

William H. Maisel, MD, MPH Should Terminology For Medical Devices Be Different? EXAMPLE: Images from Google Image Search

William H. Maisel, MD, MPH Communication Different Meanings for Different Stakeholders Example: “RECALL” FDA Definition: A firm's removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers… 21 C.F.R. § 7.1(g). My device is recalled!

William H. Maisel, MD, MPH Communication Different Meanings for Different Stakeholders Example: “RECALL” Dictionary.com Definition: A summons by a manufacturer or other agency for the return of goods or a product already shipped to market or sold to consumers but discovered to be defective, contaminated, unsafe, or the like. FDA Definition: A firm's removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers… 21 C.F.R. § 7.1(g). They said I need my device removed! My device is recalled!

William H. Maisel, MD, MPH Emerging and Uncertain Risk Business as Usual

William H. Maisel, MD, MPH NOTIFY DON’T NOTIFY Emerging and Uncertain Risk Informed Consent Facilitate Additional Data Collection Accelerate Definitive Answer Regarding Performance Issue May Improve Patient Care Increase Patient Anxiety May Not Turn Out to be True Performance Issue Adverse Impact on Industry May Adversely Affect Patient Care

William H. Maisel, MD, MPH Eliminate the term “recall” in public communications concerning implanted devices Standardized physician and patient communication Direct patient notification after first notifying physicians October 2006

William H. Maisel, MD, MPH October 2006 Importance of Clinical Recommendations/Perspective

William H. Maisel, MD, MPH Emerging and Uncertain Risks Conclusions Timely, accurate communication is critical. Efforts to standardize and develop terminology by product type (ex: medical devices) to better communicate the intended message should be undertaken. Survey specific audiences (ex: device-dependent patients) to determine which terms best convey the intended message. Professional medical societies can: Provide clinical perspective Facilitate delivery of audience-specific messages to educate and inform physicians, patients, and the media

William H. Maisel, MD, MPH Questions?? Contact: Donna Goldberg, MPH Scientific and Clinical Documents Manager Heart Rhythm Society 1400 K Street NW, Suite 500 Washington, DC (202) FDA Risk Communication Advisory Committee August 14, 2008